Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Lars Fogh Iversen

Senior Vice President, Global Research Technologies, Novo Nordisk A/S

Lars Fogh Iversen, PhD, is Senior Vice President and Head of Global Research Technologies at Novo Nordisk A/S. He is responsible for driving drug innovation at Novo Nordisk across all therapy areas (Diabetes, Obesity, NASH, Rare blood disorders, Rare endocrine disorders, Chronic Kidney and Cardiovascular Disease). This is achieved by discovering new molecules, designing new processes and engineering new formulations with the overall goal of bringing new innovative therapy treatments to patients.

Lars has been an employee of Novo Nordisk since 1997 and has served in various leadership roles since 2000. Lars has been heading up Global Research Technologies since its formation in 2018.

Lars Fogh Iversen holds a M.Sc in Pharmacy from the Royal Danish School of Pharmacy and a M.Sc in Human Biology from University of Copenhagen. Furthermore, Lars received a PhD in Protein Crystallography from University of York and University of Copenhagen. He has co-/authored 20+ peer-reviewed research papers and is an inventor on numerous international patent applications.